Reported Earlier, Biotricity Now Expects To Reach Milestone Of Being EBITDA Positive Before The End Of Calendar 2024

7/11/24 11:58:27 AM ET

Medical/Dental Instruments

Health Care

Get the next $BTCY alert in real time by email

Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.

Get the next $BTCY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BTCY

Date	Price Target	Rating	Analyst
11/20/2023		Buy → Neutral	H.C. Wainwright
3/7/2022	$5.00	Buy	Lake Street
11/23/2021	$6.00	Buy	HC Wainwright & Co.

More analyst ratings

$BTCY
Financials

Live finance-specific insights

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecurring technology fees, additional device sales to existing customers see continued growthReduced SG&A to $2.25 million from $3.5 million, down 35.5% compared to the same period last yearNet loss attri
11/15/24 8:15:00 AM ET
$BTCY
Medical/Dental Instruments
Health Care
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will de
11/13/24 9:42:00 AM ET
$BTCY
Medical/Dental Instruments
Health Care
SWK Holdings Provides Portfolio Update
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
10/17/24 4:15:00 PM ET
$BTCY
$DERM
$ELUT
$ETON
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)

$BTCY
Press Releases

Fastest customizable press release news feed in the world

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecurring technology fees, additional device sales to existing customers see continued growthReduced SG&A to $2.25 million from $3.5 million, down 35.5% compared to the same period last yearNet loss attri
11/15/24 8:15:00 AM ET
$BTCY
Medical/Dental Instruments
Health Care
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will de
11/13/24 9:42:00 AM ET
$BTCY
Medical/Dental Instruments
Health Care
SWK Holdings Provides Portfolio Update
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
10/17/24 4:15:00 PM ET
$BTCY
$DERM
$ELUT
$ETON
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)

Reported Earlier, Biotricity Now Expects To Reach Milestone Of Being EBITDA Positive Before The End Of Calendar 2024

Chat with this insight

Recent Analyst Ratings for
$BTCY

$BTCY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Biotricity downgraded by H.C. Wainwright

Lake Street initiated coverage on Biotricity with a new price target

HC Wainwright & Co. initiated coverage on Biotricity with a new price target

$BTCY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Rosa David A

SEC Form 4 filed by Al-Siddiq Waqaas

SEC Form 4 filed by Ayanoglou John

$BTCY
Financials

Live finance-specific insights

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

SWK Holdings Provides Portfolio Update

$BTCY
Press Releases

Fastest customizable press release news feed in the world

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

SWK Holdings Provides Portfolio Update

$BTCY
SEC Filings

Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Biotricity Inc.

SEC Form 25-NSE filed by Biotricity Inc.

$BTCY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

SEC Form SC 13G filed by Biotricity Inc.

$BTCY
Market Insights

Live Market Insights

Biotricity's AI Cloud Upgrades Drive Operational Gains and Path to Profitability

Biotricity shares are trading higher after the company announced that it expects to reach a milestone of being EBITDA positive.

Reported Earlier, Biotricity Now Expects To Reach Milestone Of Being EBITDA Positive Before The End Of Calendar 2024

Reported Earlier, Biotricity Now Expects To Reach Milestone Of Being EBITDA Positive Before The End Of Calendar 2024

Chat with this insight

Recent Analyst Ratings for $BTCY

$BTCY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Biotricity downgraded by H.C. Wainwright

Lake Street initiated coverage on Biotricity with a new price target

HC Wainwright & Co. initiated coverage on Biotricity with a new price target

$BTCY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Rosa David A

SEC Form 4 filed by Al-Siddiq Waqaas

SEC Form 4 filed by Ayanoglou John

$BTCY Financials

Live finance-specific insights

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

SWK Holdings Provides Portfolio Update

$BTCY Press Releases

Fastest customizable press release news feed in the world

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

SWK Holdings Provides Portfolio Update

$BTCY SEC Filings

Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Biotricity Inc.

SEC Form 25-NSE filed by Biotricity Inc.

$BTCY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

SEC Form SC 13G filed by Biotricity Inc.

$BTCY Market Insights

Live Market Insights

Biotricity's AI Cloud Upgrades Drive Operational Gains and Path to Profitability

Biotricity shares are trading higher after the company announced that it expects to reach a milestone of being EBITDA positive.

Reported Earlier, Biotricity Now Expects To Reach Milestone Of Being EBITDA Positive Before The End Of Calendar 2024

Recent Analyst Ratings for
$BTCY

$BTCY
Analyst Ratings

$BTCY
Insider Trading

$BTCY
Financials

$BTCY
Press Releases

$BTCY
SEC Filings

$BTCY
Large Ownership Changes

$BTCY
Market Insights